spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Merck Introduces Parteck® COAT Excipient, a Fast-Dissolving Material for Immediate Release Coating

Merck


• Designed to simplify the formulation and coating process for tablets
• Optimized particle size leads to fast dissolving and increases coating process efficiency

Merck has launched its Parteck® COAT excipient, a new functional material designed for immediate release film coating applications. Parteck® COAT is a particle engineered polyvinyl alcohol (PVA) with a unique particle structure that enables rapid dissolution even at low temperatures leading to an increased process efficiency.

Merck is the only supplier to offer a fast-dissolving PVA for coating applications. The water-soluble particle offers reliable batch-to-batch consistency, contributing to the quality and performance of the final drug product.

Parteck® COAT offers low viscosity in solution, even at high concentrations of 20 percent, leading to higher efficacy. Compared with existing PVAs for coating applications, Parteck® COAT has the potential to double the polymer concentration and cut the process time in half along with the following advantages:
• A stable moisture barrier to improve stability of moisture-sensitive drug substances.
• Excellent surface finishing to increase the value of drug formulations.
• A high concentration of spraying liquid to increase coating efficacy.

Parteck® COAT is compliant with and surpasses the requirements of all major pharmacopoeias, including United States Pharmacopoeia (USP), European Pharmacopoeia (Ph. Eur.), Chinese Pharmacopoeia (ChP) and Japanese Pharmaceutical Excipients (JPE).

The new excipient will be incorporated into Merck’s Emprove® program. This program provides customers instant, online access to regulatory and technical information about the excipient and more than 400 other chemicals, as well as filters and single-use components to facilitate risk assessment and qualification processes.

Experts from Merck will be available at booth #1037 at the American Association of Pharmaceutical Scientists’ PharmSci 360 conference in San Antonio, Texas to discuss Parteck® COAT and the entire Emprove® portfolio.
phone +33 (0)5 57 960 960
email Sebastien.ribault@merckgroup.com
web www.merckmillipore.com/adaptive-CDMO
email 1 rue Jacques Monod, Site Montesquieu, 33650 Martillac, France
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Merck to Provide BioReliance® End-to-End Solutions to Phanes Therapeutics

• Collaboration to accelerate development and manufacturing of Bispecific Antibody • Merck plans to offer Phanes a full suite of products and services under its BioReliance® offering
More info >>


White Papers

Interface: Drug Delivery Devices

Phillips-Medisize

A family is packing for its annual summer trek to the cottage by the lake. Along with fishing gear, sunscreen, and life vests, the checklist also includes another kind of life saver – an autoinjector that delivers two doses of epinephrine to treat anaphylaxis, a severe and potentially lifethreatening allergic reaction.
More info >>

Industry Events

ESMO Targeted Anticancer Therapies Congress 2020

2-4 March 2020, Paris, France

A unique and international mix of experts, researchers and decision makers both from academia and industry across the globe, will convene in Paris for a three-day Congress aiming at exchanging knowledge, experience and research innovations in cancer. TAT 2020 will focus, among others, on novel strategies in immuno-oncology, personalised medicine and molecular tumour boards, preclinical studies to identify effective combination therapies, use of microbiome, tumour agnostic trials, ADC technology, oncolytics, multispecific biological constructs and targeting cytokines. Participating in TAT 2020 will offer you the possibility to take part in interdisciplinary discussions inspiring new ideas and new collaborations.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement